PHV-wordings
Here you will find safety-relevant information that must be implemented in the corresponding product information due to a PHV issues.
Due to the relaunch of the EMA website in December 2023, you will find the current links to the entries prior to December 01, 2023 at https://www.ema.europa.eu
Levomethadone
PSUR-outcome
|
13/03/2020
Further information and amendments to the product information in all EU languages can be found on the EMA website.
Sulfametrole / Trimethoprim, Sulfadiazine / Trimethoprim, Sulfamethoxazole / Trimethoprim (Co-trimoxazole)
PSUR-outcome
|
11/03/2020
Further information and amendments to the product information in all EU languages can be found on the EMA website.
Tolperisone
PSUR-outcome
|
11/03/2020
Further information and amendments to the product information in all EU languages can be found on the EMA website.
Moxifloxacin (systemic use)
PSUR-outcome
|
11/03/2020
Further information and amendments to the product information in all EU languages can be found on the EMA website.
Levonorgestrel
PSUR-outcome
|
10/03/2020
Further information and amendments to the product information in all EU languages can be found on the EMA website.
Olanzapine
PSUR-outcome
|
10/03/2020
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Valaciclovir
PSUR-outcome
|
10/03/2020
Further information can be found on the HMA website.
Pramipexole
PSUR-outcome
|
10/03/2020
Further information can be found in the Commission Decision and its annexes, which are available in all EU languages on the European Commission's (EC) website.
Rocuronium
PSUR-outcome
|
17/02/2020
Further information and amendments to the product information in all EU languages can be found on the EMA website.
Ethinylestradiol / Levonorgestrel
PSUR-outcome
|
30/01/2020
Further information and amendments to the product information in all EU languages can be found on the EMA website.
